Extraction of prostate cancer stem cells using self-designed magnetic beads

doi:10.3969/j.issn.2095-4344.2016.01.007

Abstract

Abstract:

BACKGROUND: Effective sorting of prostate cancer stem cells is the basis of experimental studies in prostate cancer developing. The most common sorting method is magnetic-activated cell sorting.
OBJECTIVE: To separate CD133+/CD44+ cells in prostate cancer tissues using self-designed magnetic beads followed by culture, passage and immunological identification.
METHODS: Self-designed magnetic microspheres were applied to establish immunomagnetic beads to sort CD133+/CD44+ cells in prostate cancer tissues. The sorted cells were cultured in serum-free medium. The sphere formation, cell morphology, and proliferation ability after cell passage were statistically compared between the sorted cells and the normal tumor cell lines. Immunofluorescence detection was performed to detect the expression of specific antibodies.
RESULTS AND CONCLUSION: Self-designed immunomagnetic beads had small diameter and a high-sorting effect. The sorted cells possessed a high capacity of microsphere formation. After cell culture and passage, the cells highly expressed CD133 and CD44 antigens. The sorted cells with no induction had varying shapes and grew vigorously. After induction with transforming growth factor-β, the cultured cells were noted to have a single shape and grow slowly. The cell proliferation ability of sorted cells in these two groups differed significantly from that of the normal cancer cell lines (both P < 0.05). In conclusion, the CD133+/CD44+ cells sorted from prostate tumor cells possessed cell morphology and function characteristics of stem cells which can provide a basis for extraction and culture of prostate cancer stem cells.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

CLC Number:

R394.2

Gong Rui, Li Sheng-ying, Huo Zhi-xia, Ding Hao, Sun Er-lin . Extraction of prostate cancer stem cells using self-designed magnetic beads[J]. Chinese Journal of Tissue Engineering Research, 2016, 20(1): 36-41.

Figures/Tables 5

References

[1] Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009;461(7263):495-500.

[2] Iwata T, Schultz D, Hicks J, et al. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One. 2010;5(2):e9427.

[3] Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science. 2010;329(5991): 568-571.

[4] Lawson DA, Zong Y, Memarzadeh S, et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010;107(6):2610-2615.

[5] Maitland NJ, Frame FM, Polson ES, et al. Prostate cancer stem cells: do they have a basal or luminal phenotype. Horm Cancer. 2011;2(1):47-61.

[6] Choy W, Nagasawa DT, Trang A, et al. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Neurosurg Clin N Am. 2012;23(3):391-405.

[7] Lee HJ, You DD, Choi DW, et al. Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J Korean Surg Soc. 2011;81(4): 263-270.

[8] Wang C, Xie J, Guo J, et al. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 2012;28(4):1301-1308.

[9] Vander Griend DJ, Karthaus WL, Dalrymple S, et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008;68(23):9703-9711.

[10] Korski K, Malicka-Durczak A, Br?borowicz J. Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens. Pol J Pathol. 2014;65(4):291-295.

[11] Olumi AF, Grossfeld GD, Hayward SW, et al. Carcinoma- associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59(19): 5002-5011.

[12] Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23):10946-10951.

[13] Taylor RA, Toivanen R, Frydenberg M, et al. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells. 2012;30(6):1087-1096.

[14] Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science. 2010;329(5991): 568-571.

[15] Maitland NJ, Frame FM, Polson ES, et al. Prostate cancer stem cells: do they have a basal or luminal phenotype. Horm Cancer. 2011;2(1):47-61.

[16] Lawson DA, Zong Y, Memarzadeh S, et al. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010;107(6):2610-2615.

[17] Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-284.

[18] Morgan TM, Lange PH, Vessella RL. Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci. 2007;12:3000-3009.

[19] Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38(5):696-701.

[20] Reynolds MA, Kastury K, Groskopf J, et al. Molecular markers for prostate cancer. Cancer Lett. 2007;249(1):5-13.

[21] Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett. 2008;271(1):13-24.

[22] Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Anticancer Res. 2009;29(8):3289-3298.

[23] Gong R, Li S. Extraction of human genomic DNA from whole blood using a magnetic microsphere method. Int J Nanomedicine. 2014;9:3781-3789.

[24] Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25(12):1696-1708.

[25] Vander Griend DJ, Karthaus WL, Dalrymple S, et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 2008;68(23):9703-9711.

[26] Tang B, Yoo N, Vu M, et al. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res. 2007;67(18): 8643-8652.

[27] Mickey DD, Stone KR, Wunderli H, et al. Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res. 1977;37(11):4049-4058.

[28] Okada H, Shirakawa T, Miyake H, et al. Establishment of a prostatic small-cell carcinoma cell line (SO-MI). Prostate. 2003;56(3):231-238.